Inhibitor Therapeutics, Inc.

Equities

INTI

US45720M1053

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:29:55 2024-05-16 EDT			5-day change	1st Jan Change
0.089 ^USD	+0.03%		-26.20%	-3.26%

03-29	Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	CI

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 13, 2021 at 09:02 am

Inhibitor Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 62,635 compared to USD 315,044 a year ago. Net loss was USD 66,182 compared to USD 314,894 a year ago. For the half year, operating loss was USD 230,388 compared to USD 700,486 a year ago. Net loss was USD 194,020 compared to USD 699,311 a year ago.

Latest news about Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	12-19	CI
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome	12-19	CI
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University	12-14	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee	23-10-18	CI
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board	23-08-29	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Inhibitor Therapeutics, Inc. Announces Board Changes	23-05-31	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Inhibitor Therapeutics, Inc. Announces Retirement of Debra Peattie from the Board of Directors	22-06-03	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Inhibitor Therapeutics, Inc. Executes A Letter Agreement with Mayne Pharma to Amend the Loan Agreement and the Facility	22-01-18	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-26	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	21-03-25	CI
Inhibitor Therapeutics, Inc. and Mayne Pharma Ventures Pty Ltd Enters Into Loan Agreement	20-12-17	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI

Chart Inhibitor Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBITOR THERAPEUTICS, INC.	-3.26%	15.31M
VERTEX PHARMACEUTICALS INCORPORATED	+9.39%	114B
REGENERON PHARMACEUTICALS, INC.	+11.50%	104B
BIONTECH SE	-13.97%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.44%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+6.87%	14.28B
SAREPTA THERAPEUTICS, INC.	+35.29%	12.55B

Bio Therapeutic Drugs